Skip to main content
Premium Trial:

Request an Annual Quote

Scienion, Axela Ink Joint Array Development Agreement

NEW YORK (GenomeWeb) – German sample preparation firm Scienion and Canadian molecular diagnostics firm Axela today announced they have signed a joint marketing and development agreement to create and sell production systems and services for diagnostic and research products.

"This will provide commercialization partners with an integrated and scalable offering to address emerging diagnostic markets," including oncology, allergy, infectious disease, and other markets, the firms said in a statement.

Axela sells a variety of flow-through array technologies. "Our printing requirements are unique," Axela President Paul Smith said. "A precise and versatile liquid handling technology was necessary to meet these demanding requirements, while still providing our partners with a robust, go-to market production solution."

Financial and other details of the agreement were not disclosed.

Over the past year, Scienion has partnered with several firms including Grenier Bio-One, Axxin, Anteo, and QuantuMDx to incorporate its liquid handling and other sample prep technologies into various diagnostic tests and platforms.

Recently, Axela launched a collaboration with Pathology Associates Medical Laboratories to create multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.